8TO3

EGFR(T790M/V948R) in complex with LN5461

8TO3 の概要

• エントリーDOI: 10.2210/pdb8to3/pdb
• 分子名称: Epidermal growth factor receptor, MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER, ... (5 entities in total)
• 機能のキーワード: cancer, inhibitor, kinase, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 152231.83

構造登録者

Chitnis, S.P.,Pham, C.D.,Heppner, D.E. (登録日: 2023-08-02, 公開日: 2024-08-28, 最終更新日: 2026-03-04)

主引用文献

Wittlinger, F.,Chitnis, S.P.,Pham, C.D.,Damghani, T.,Patel, K.B.,Mollers, M.,Schaeffner, I.K.,Abidakun, O.A.,Deng, M.Q.,Ogboo, B.C.,Rasch, A.,Beyett, T.S.,Buckley, B.,Feru, F.,Shaurova, T.,Knappe, C.,Eck, M.J.,Hershberger, P.A.,Scott, D.A.,Brandt, A.L.,Laufer, S.A.,Heppner, D.E.
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.
J.Med.Chem., 67:21438-21469, 2024

PubMed Abstract: Binding multiple sites within proteins with bivalent compounds is a strategy for developing uniquely active agents. A new class of dual-site inhibitors has emerged targeting the epidermal growth factor receptor (EGFR) anchored to both the orthosteric (ATP) and allosteric sites. Despite proof-of-concept successes, enabling selectivity against oncogenic activating mutations has not been achieved and classifying these inhibitors among kinase inhibitors remains underexplored. This study investigates the structure-activity relationships, binding modes, and biological activity of ATP-allosteric bivalent inhibitors (AABIs). We find that AABIs selectively inhibit drug-resistant EGFR mutants (L858R/T790M and L858R/T790M/C797S) by anchoring a methyl isoindolinone moiety along the αC-helix channel of the allosteric site. In contrast, related Type I/ inhibitors target wild-type EGFR but are less effective against resistant mutants. This shift in selectivity demonstrates that mutant-selective AABIs classify as "Type V" bivalent inhibitors.

PubMed: 39626019
DOI: 10.1021/acs.jmedchem.4c02311

実験手法

X-RAY DIFFRACTION (2.49 Å)